Navigation Links
Mylan Announces Upsizing and Pricing of Senior Notes
Date:5/12/2010

e unlawful prior to registration or qualification under the securities laws of any such state.

About Mylan

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

Forward-Looking Statements

This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to Mylan's failure to consummate the private placement or to utilize the proceeds of such placement as described in this press release. These cautionary statements should be considered in connection with any subsequent written or oral forward-looking statements that may be made by Mylan or by persons acting on its behalf and in conjunction with its periodic SEC filings. In addition, please refer to the cautionary statements and risk factors set forth in Mylan's Quarterly Report o
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... ST. LOUIS, July 29, 2014  Express Scripts Holding ... quarter net income attributable to Express Scripts stockholders of ... per diluted share, as detailed in Table 4, was ... "We are well positioned to serve our clients with ... and to improve the health outcomes of our members," stated ...
(Date:7/29/2014)... 2014  EnteroMedics Inc. (NASDAQ: ETRM ), ... treat obesity, metabolic diseases and other gastrointestinal disorders, today ... Thursday, August 7, 2014 at 11:00 AM Eastern Time ... June 30, 2014 and to provide a business update. ... quarter conference call may be accessed by dialing (877) ...
(Date:7/29/2014)... 2014 New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. The study finds that the ...
Breaking Medicine Technology:Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 8Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 9Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 10Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 11Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 12Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 13Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 14Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 15Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 16Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 17Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 18Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 19Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 20Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 21Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 22Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 23Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 24Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 26Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 27Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 28Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 29Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 30Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 31EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... April 14, 2011 Oxford Finance Corporation (Oxford), a ... a $2 million equipment loan with Synta Pharmaceuticals Corp. ... compounds for use in Synta,s ongoing clinical trials in ... "Synta Pharmaceuticals has a diverse drug pipeline, including ...
... (NYSE: BT ) shared its vision of ... cloud computing strategies to pharma research at the Bio-IT ... This vision reflects BT,s strong capabilities and increasing specialization ... world,s leading pharmaceutical companies rely on BT to support ...
Cached Medicine Technology:Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp. 2BT Pushes for R&D Innovation at Bio-IT World Conference 2BT Pushes for R&D Innovation at Bio-IT World Conference 3
(Date:7/29/2014)... 29, 2014 As the Ebola outbreak in ... partners to both purchase critical emergency supplies locally, as well ... Liberia. These supplies will contain materials used to control the ... populated areas of the country. , With a large ... response to the Ebola outbreak in the region. The current ...
(Date:7/29/2014)... Los Angeles, CA (PRWEB) July 29, 2014 ... on the website of Time Magazine titled “From Kim’s ... Want,” Kim Kardashian’s butt is the celebrity ... celebrities and their features include Beyoncé’s butt, Jennifer ... and lips. This information is based on data collected ...
(Date:7/29/2014)... Las Vegas, Nevada (PRWEB) July 29, 2014 ... has reappointed Holland & Hart LLP ’s Connie ... Bar Foundation. She currently serves as President of the Foundation. ... from 2011-2012. , Akridge is a partner at Holland & ... variety of litigation and regulatory/administrative matters to insurance and healthcare ...
(Date:7/29/2014)... 2014) Using quality improvement measures in eight of ... Disease Study Group, researchers have found a way to ... contrast dye. , Currently, 7-15 percent of these patients ... up with kidney injury, which can result in death ... or permanent dialysis, says a study published in the ...
(Date:7/29/2014)... July 29, 2014 CarePoint Health ... have joined our network, CarePoint Health Medical Group. ... Sushma Kaki. Hundreds of highly skilled and experienced ... network of top doctors and practices in Hudson ... latest acquisition represents CarePoint Health’s commitment to provide ...
Breaking Medicine News(10 mins):Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 2Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 3Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:Reducing kidney injury using a quality improvement method 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 3
... 21 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, ... has closed its previously announced public offering (the ... $12.65 million. , The Company issued 73,333,333 Units ... "Offering Price"). The Company concurrently issued an additional ...
... Couples using assisted reproductive technology should be made aware, ... -- Compared to naturally conceived twins, those conceived through ... hospitalized and admitted to neonatal intensive care, finds a ... for all twins born in Western Australia between 1994 ...
... New White Paper Outlines Possible Ways to Improve ... Today, during a Partnership to Fight Chronic ... researchers Michael J. O,Grady, Ph.D., and James C. ... Projections for Diabetes and other Chronic Diseases: The ...
... Indicator of Demand for Well-Priced New and Refurbished ... Despite numerous negative earnings announcements, the demand ... to be robust during the current economic downturn. ... refurbished ultrasound solutions, reported a 118 percent increase ...
... May 21 CPC of America, Inc. (OTC Bulletin ... patent of a synthetic sealant for specific application to ... development and testing of the MedClose(TM) VCS, which is ... diagnostic and interventional procedures. In addition, CPC is ...
... May 21 Genomic Health, Inc. (Nasdaq: ... results from three studies at the American Society of ... - June 2, 2009, at the Orange County Convention ... widely-adopted Onco type DX(R) breast cancer test, which ...
Cached Medicine News:Health News:Response Biomedical Closes $12.65 million Unit Offering 2Health News:Response Biomedical Closes $12.65 million Unit Offering 3Health News:Response Biomedical Closes $12.65 million Unit Offering 4Health News:Fertility Treatment Twins More at Risk for Hospitalizations 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 3Health News:MedPro Imaging Reports 118 Percent Growth For First Quarter 2Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 2Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 3Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 2Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 3
LUMIGAN® is a powerful eye drop medication for lowering IOP. IOP is short for intraocular pressure or eye pressure. LUMIGAN® is the first in a new class of medication....
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.15% is medication in the form of an eye drop that is used to lower the pressure inside your eye(s), also referred to as intraocular pressu...
Medicine Products: